|
J Biol Chem, Vol. 273, Issue 35, 22672-22680, August 28, 1998
Specificity of Prohormone Convertase 2 on Proenkephalin and
Proenkephalin-related Substrates*
Karla
Johanning ,
Maria A.
Juliano§¶,
Luiz
Juliano§¶,
Claude
Lazure ,
Nazarius S.
Lamango ,
Donald
F.
Steiner**, and
Iris
Lindberg 
From the Department of Biochemistry and Molecular
Biology, Louisiana State University Medical Center, School of
Medicine, New Orleans, Louisiana 70112, the § Department
of Biophysics, Escola Paulista de Medicina, Rua Tres de Maio 100, 04044-020, Sao Paulo, Brazil, the Neuropeptide Structure and
Metabolism Laboratory, Institut de Recherches Cliniques de
Montreal, Montreal, Quebec, Canada 2W 1R7, and the ** Howard Hughes
Medical Institute and Department of Biochemistry, University of Chicago
Medical School, Chicago, Illinois 60637
 |
ABSTRACT |
In the central and peripheral nervous
systems, the neuropeptide precursor proenkephalin must be
endoproteolytically cleaved by enzymes known as prohormone convertases
1 and 2 (PC1 and PC2) to generate opioid-active enkephalins. In this
study, we have investigated the specificity of recombinant mouse PC2
for proenkephalin-related internally quenched (IQ) peptides, for
methylcoumarin amide-based fluorogenic peptides, and for recombinant
rat proenkephalin. IQ peptides exhibited specificity constants
(kcat/Km) between 9.4 × 104 M 1 s 1
(Abz-Val-Pro-Arg-Met-Glu-Lys-Arg-Tyr-Gly-Gly-Phe-Met-Gln-EDDnp; where
Abz is ortho-aminobenzoic acid and EDDnp is
N-(2,4-dinitrophenyl)ethylenediamine)) and 0.24 × 104 M 1 s 1
(Abz-Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-EDDnp), with the
peptide B to Met-enk-Arg-Phe cleavage preferred (Met-enk is
met-enkephalin). Fluorogenic substrates with P1, P2, and P4 basic amino
acids were hydrolyzed with specificity constants ranging between
2.0 × 103 M 1
s 1 (Ac-Orn-Ser-Lys-Arg-MCA; where MCA is methylcoumarin
amide) and 1.8 × 104 M 1
s 1 (<Glu-Arg-Thr-Lys-Arg-MCA; where <Glu is
pyroglutamic acid). Substrates containing only a single basic residue
were not appreciably hydrolyzed, and substrates lacking a P4 Arg
exhibited kcat of less than 0.05 s 1. Substitution of ornithine for Lys at the P4 position
did not significantly affect the kcat but
increased the Km 2-fold. Data from both sets of
fluorogenic substrates supported the contribution of a P4 Arg to PC2
preference. Analysis of proenkephalin reaction products using
immunoblotting and gel permeation chromatography demonstrated that PC2
can directly cleave proenkephalin and that the generation of small
opioid peptides from intermediates is mediated almost entirely by PC2
rather than by PC1. These results are in accord with the analysis of
PC2 knock-out brains, in which the amounts of three mature enkephalins
were depleted by more than three-quarters.
 |
INTRODUCTION |
Prohormones and proneuropeptides are synthesized as inactive large
precursors that are proteolytically cleaved during intracellular transport to generate active peptide forms for extracellular release (1, 2). Pairs of basic amino acid residues such as Lys-Arg and Arg-Arg-
and to a certain extent Lys-Lys and Arg-Lys- have been recognized as
consensus sites of proteolytic cleavage (1, 2). Primary and secondary
structures in proproteins are thought to be important for enzyme
recognition and selectivity of cleavage (1-3). The involvement of
prohormone convertases 1 and 2 (PC11 and PC2), serine
proteinases expressed in neuroendocrine tissues, in precursor cleavage
has been widely accepted (1, 2) although other enzymes have recently
also been reported to be involved in opioid peptide precursor cleavage
(4).
Previous reports from our laboratory using cell-based systems have
provided support for the idea that PC1 is the chief enzyme concerned
with the generation of intermediate-sized peptides from proenkephalin
(PE) and that PC2 is mostly responsible for the production of small,
bioactive opioid peptides (5, 6). The profile of peptides generated in
PE-expressing AtT-20 cells (7), which contain high quantities of
endogenous PC1 (8), consists mainly of 3-18-kDa enkephalin-containing
peptides, although some mature enkephalins such as Met-enk-Arg-Phe and
Met-enk are also present (7). In contrast, the major PE products in
PC2-containing AtT-20/PE cells, as well as in PC2-expressing Rin-PE
cells, are the fully processed opioid peptides Met-enk-Arg-Phe,
Met-enk-Arg-Gly-Leu, Met-enk, and Leu-enk (6, 7). In agreement with the
notion that PC2 expression is correlated with more complete processing of PE, antisense experiments have shown that PC2 is largely responsible for the processing of PE into smaller opioid peptides in Rin cells (6).
These data imply that PC2 can cleave at a wider range of sites within
PE than PC1; however, the structural factors that differentiate PC1
from PC2 cleavage sites remain unclear.
Since the PCs have only recently become available in recombinant form
(9-12), there is limited information on their reaction and kinetics
with natural substrates. Examples of studies on the cleavage of
naturally occurring peptides by recombinant PC1 include the cleavage of
proopiomelanocortin (13), anthrax toxin-protective antigen (14)
pro-thyrotropin-releasing hormone by PC1 (15), prodynorphin (16), and
proalbumin (17). Studies of recombinant PC2 cleavage on natural
substrates include proglucagon (18, 19), cholecystokinin-33 (20), and
prodynorphin (21). Comparative work on both enzymes includes reports on
the cleavage of proneuropeptide Y (22) and proinsulin (23, 24). Taken
together, this work supported the idea that both prohormone convertases
prefer paired basic cleavage sites containing a P4 basic residue and
can cleave at single basic residues given the presence of additional
amino-terminal basic residues. However, in general, work with natural
substrates has not revealed additional preferences for residues
surrounding the cleavage site. Synthetic fluorogenic and internally
quenched peptides and methylcoumarin amide (MCA)-containing substrates have been used to determine kinetic parameters of subtilisin-like enzymes and to explore the structural features surrounding the dibasic
cleavage sites that contribute to enzyme specificity (25, 26). In this
study we have investigated the kinetic properties of PC2 against
proenkephalin-related internally quenched substrates and a series of
fluorogenic peptides. In addition, we examined the hydrolysis of
recombinant PE in vitro by PC1 and PC2. Finally, we have
used PC2 knock-out mice (27) to confirm the involvement of this enzyme
in the natural processing of PE.
 |
MATERIALS AND METHODS |
Internally Quenched Fluorescent Peptide Substrates--
To
determine the specificity of PC2 for proenkephalin-derived peptides,
internally quenched Abz-peptidyl-EDDnp substrates (where Abz is
ortho-aminobenzoic acid and EDDnp is N-(2,
4-dinitrophenyl)ethylenediamine) were synthesized and purified as
described previously (28, 29). The molecular weight and purity of
synthesized peptides were checked by mass spectroscopy laser desorption
ionization-time of flight (MALDI-TOF) using TofSpec-E from Micromass.
In these intramolecularly quenched peptides the Abz group is attached
to the amino terminus and the EDDnp moiety to a carboxyl-terminal
glutamine, necessary for the solid-phase peptide synthesis (29). A
total of 11 substrates, 11-12 amino acids in length, was synthesized
corresponding to the sequences surrounding PE cleavage sites (Fig. 1).
In addition, another set of 10 substrates was synthesized that
corresponded to analogs of a 12-residue peptide B-like sequence
(Abz-VPEMEKRYGGFMQ-EDDnp). In the latter peptides, Arg and Ala were
substituted at various positions from P3 to P7 to determine the effect
of sequence preference. To investigate the potential requirement for
length, an extended peptide B-related substrate was synthesized
(Abz-LPSDEEGESYSKEVPEMEKRYGGFMQ-EDDnp).
Purification of Recombinant mPC2--
Recombinant mPC2 was
overexpressed in Chinese hamster ovary cells using the dihydrofolate
reductase-coupled amplification method previously described (30); cells
were subsequently stably supertransfected with cDNAs encoding
21-kDa rat 7B2 (12). Cells were grown in a Cellmax artificial capillary
cell culture system (Cellco, Germantown, MD). PC2 was purified from 20 ml of conditioned media (in which the primary proteins present were the
71- and 75-kDa proenzyme forms) diluted 1:3 in buffer A on a 5 × 50-mm Protein-Pak anion-exchange column (Waters Chromatography,
Milford, MA) using a step gradient first from 0 to 35% B in 175 min at a flow rate of 0.25 ml/min, followed by a further gradient to 100% B
in 50 min at 0.50 ml/min. Buffer A was 20 mM Bis-Tris, 0.1% Brij, pH 6.5, and buffer B was 1 M sodium acetate, 20 mM Bis-Tris, 0.1% Brij, pH 6.5. Two-ml fractions were
collected and assessed for purity on 8.8% gels using Coomassie
staining.
Purification of Recombinant Proenkephalin and
PC1--
Recombinant rat PE was overexpressed in Chinese hamster ovary
cells using the dihydrofolate-reductase amplification method (30).
Recombinant PE was purified from the conditioned medium essentially as
described previously (30) using a 4.6 × 25-mm Vydac
semi-preparative C4 column (Vydac, Hesperia, CA) by elution with 80%
acetonitrile in 0.1% trifluoroacetic acid. Recombinant PC1 was
produced by the same method, but cells were grown in a Cellmax
artificial capillary cell culture system as for PC2 (Cellco, Germantown, MD). PC1 was purified from 20 ml of conditioned medium diluted 1:3 in buffer A on a 5 × 50-mm Protein-Pak anion-exchange column (Waters Chromatography, Milford, MA) using a gradient from 0 to
100% B in 120 min. The buffers used were identical to those employed
for PC2. The flow rate was 0.50 ml/min, and 1-ml fractions were
collected. PC1 fractions were assessed for purity as above.
kcat/Km Determinations of Internally Quenched
Peptides--
The actual concentration of each substrate was
determined using a spectrophotometer by measuring the EDDnp absorbance
at 365 nm (EDDnp extinction coefficient, 17, 300 M 1). A stock solution of 1 mM
peptide was prepared in dimethyl sulfoxide. Internally quenched
substrates (final dilutions of 2 µM and 200 nM) were subjected to digestion by recombinant mouse PC2 at
37 °C in a buffer containing 100 mM sodium acetate, pH
5.0, 5 mM calcium chloride, and 0.1% Brij in a total
volume of either 1 ml or 250 µl. Cuvettes and buffer were kept at
37 °C prior to the addition of substrate. Recombinant pro-PC2 was
diluted 1:3 with the above buffer and incubated for 20 min at 37 °C
to obtain the 66-kDa autoactivated form of this enzyme (12). The
specific activity of the preparation under saturating substrate
concentrations was 29 µmol/h/mg. Substrate was added to reaction
buffer in the cuvette, and the cuvette was placed in the thermostated
fluorometer (37 °C) for equilibration. Abz fluorescence of each
substrate was measured with a Perkin-Elmer fluorometer
( excitation = 320 nm; emission = 420 nm) at time 0 and
was recorded at various points after the addition of PC2 (36 nM final concentration). These reaction conditions represent pseudo first-order conditions. Fluorescence data were fitted
to a first-order curve by nonlinear regression (one phase exponential
decay) using GraphPad version 2.0 (ISI Software, CA) as shown in
Equation 1.
|
(Eq. 1)
|
where Y is the amplitude of the fluorescence change;
k is the apparent first- order rate constant; and plateau is
the fluorescence at the end point of the reaction. The resultant
apparent first-order rate constants were divided by the moles of enzyme
(as calculated from the protein concentration and assuming a molecular
mass of 66 kDa for activated PC2). These experiments were always
performed in duplicate and, for the three best substrates of each
group, at two different substrate concentrations. In addition, six IQ substrates (Fig. 1, 1, 2, 5, 7, 9, and 10) were
subjected to PC1 digestion under the same pseudo first-order rate
conditions (2 µM substrate). PC1 (115 nM
final) was preincubated in 100 mM sodium acetate, pH 5.5, 5 mM calcium chloride, 0.1% Brij for 1 h in order to
attain linear cleavage rates (9). The enzyme was then added to the
substrate as described above for PC2 digestions in a total volume of 1 ml.
To verify cleavage at the dibasic pair, each Abz-peptidyl-EDDnp
substrate (100 µM) was incubated overnight with PC2 (5 nM) in the same reaction mixture as described above for
subsequent isolation of the product by HPLC and was identified by mass
spectroscopy (MALDI-TOF).
Hydrolysis of Methylcoumarin Amide (MCA) Substrate
Series--
Custom synthesis of Cbz-Arg-Ser-Lys-Arg-MCA (where Cbz is
benzyloxycarbonyl) was performed by Enzyme Systems Products (Dublin, CA) and verified by amino acid composition. The 7B2 hCT1-31 peptide was
synthesized by LSUMC Core Laboratories. Boc-Gly-Arg-Arg-MCA, Boc-Gly-Lys-Arg-MCA, Boc-Val-Pro-Arg-MCA, Boc-Val-Leu-Lys-MCA, and
<Glu-Arg-Thr-Lys-Arg-MCA were purchased from Peptides International, Inc. (Louisville, KY). All other fluorogenic substrates were
synthesized at the Clinical Research Institute of Montreal, Canada, as
described elsewhere (31). A series of MCA-based fluorogenic substrates was tested for hydrolysis rates by PC2 (3.7 to 260 ng, depending on the
rate of hydrolysis) in 100 mM sodium acetate buffer, pH 5.0, containing 5 mM calcium chloride, 0.1% Brij, and 100 nM 21-kDa 7B2 (which stabilizes the enzyme; Ref. 12) at
37 °C. Various concentrations of the different peptides were used,
as indicated in the figure legends, and the rates of hydrolysis were
determined by fluorometry. The background fluorescence in each
substrate at the start of incubation was subtracted from the final
values. Km and Vmax values
were obtained by applying Michaelis-Menten kinetics to the data using
the Enzfitter program (Elsevier-Biosoft).
Fluorogenic Peptide Enzyme Assays--
PC assays were performed
in duplicate at 37 °C in a buffer consisting of 100 mM
sodium acetate, 5 mM calcium chloride, and 0.1% Brij
(final concentrations); the pH of the sodium acetate buffer in
PC1-containing reactions was 5.5, and the pH of PC2-containing reactions was 5.0. Activity was estimated using the fluorogenic substrate <Glu-Arg-Thr-Lys-Arg-MCA. For
kcat/Km determinations, pro-PC2 was preincubated in assay buffer for 20 min at 37 °C for conversion to the 66-kDa active form (12). The reactions were initiated
by the addition of substrate. All reactions were carried out in a
50-µl total reaction volume in a polypropylene microtiter plate as
described previously (12). Free amino methyl coumarin was measured with
a Cambridge Technology microtiter plate fluorometer (Watertown, MA) at
excitation = 380 nm and emission = 460 nm.
Proenkephalin Cleavage by PC1 and PC2--
For the time course
digestion experiment PC1 and PC2 (0.24 µg; 55 and 72 nM
final concentrations, respectively) were preincubated at the
appropriate pH values (1 h for PC1 at pH 5.5 and 20 min for PC2 at pH
5.0) as described above in a 50-µl reaction volume; recombinant rat
PE (1.25 µg; 0.91 µM final concentration)
was then added. The reaction mixtures were incubated for 0, 10, 30, 60, 90 and 120 min, at which time 1/10 volume of a 10× solution of Laemmli
sample buffer (0.5 M Tris-HCl, pH 6.8, 5%
-mercaptoethanol, 10% glycerol, 2% SDS, and 0.06 mg/ml bromphenol
blue) was added. Samples were then boiled, and a tenth of the reaction
mixture was subjected to electrophoresis on a 10-20%
SDS-polyacrylamide gradient gel (Bio-Rad). Proteins were then
transferred to nitrocellulose and subjected to Western blotting as
described previously (6). The antiserum used was raised against peptide
F (32) and recognizes proenkephalin as well as PE cleavage products
containing peptide F. Chromaffin granule total protein (about 20 µg)
was subjected to electrophoresis to compare the pattern of natural
cleavage products to those resulting from the digestion with PC1 and
PC2. All experiments were repeated at least twice.
Radioimmunoassay and Size Separation of PE Digestion
Products--
PE (450 nM final concentration) was
incubated with preincubated PC2 (40 nM) in 100 mM acetate buffer, pH 5.0, at 37 °C for 30 min. The
reaction mixture was then acidified with trifluoroacetic acid (0.1%
final concentration) and frozen until HPGPC, performed as described
previously (33). HPGPC fractions were collected into polypropylene
tubes to which 5 µg of bovine serum albumin had been added as
carrier. Duplicate aliquots of each fraction were subjected to
enkephalin radioimmunoassay as described previously (34), either
untreated or following treatment with trypsin and carboxypeptidase B
(35) to reveal cryptic enkephalin sequences and to remove
carboxyl-terminal basic amino acids that interfere with
immunoreactivity. Enkephalin antisera used were raised against Met-enk-Arg-Phe (JAS; Ref. 36), Met-enk (RB4; Ref. 37), and Leu-enk
(38). PE digestions with PC2 and RIAs were carried out at least twice
with similar results.
High Pressure Gel Permeation Analysis of Enkephalins in PC2
Knock-out and Control Mouse Brain--
Frozen brains from
PC2-knock-out and wild-type control mice were thawed and immediately
homogenized in 5 volumes of ice-cold 1 N acetic acid, 20 mM HCl, and 0.1% -mercaptoethanol. After centrifugation
at 10,000 × g for 30 min, half of the supernatant was
lyophilized and resuspended in 250 µl of 32% acetonitrile containing
0.1% trifluoroacetic acid for gel permeation analysis. High pressure
gel permeation was carried out as described previously (6) except that
the flow rate was 0.40 ml/min, and 0.40 ml was collected per fraction.
Aliquots of fractions were assayed for the various enkephalins by RIA,
in certain cases following tryptic digestion and carboxypeptidase B
trimming as described previously (35), and the results were reported
per fraction. The experiment was repeated once with a separate set of
brains.
 |
RESULTS |
Fig. 1 is a diagrammatic
representation of rat PE that depicts the different cleavage sites and
peptides known to result from proteolytic cleavage of this precursor
molecule (39). The numbers above the PE structure indicate the
11-12-residue internally quenched peptides used for studies of PC2
specificity. As shown in the diagram, peptide B is an example of an
intermediate that results from cleavage at a paired basic site and that
serves as a substrate for generation of the opioid peptide
Met-enk-Arg-Phe. Peptide E, an intermediate-sized peptide, can give
rise to both Met-enk and Leu-enk.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
Structure of rat proenkephalin and known
sites of endoproteolytic cleavage. Intermediate-sized peptides and
active enkephalins (Met-enk-Arg-Gly-Leu, Met-enk-Arg-Phe, Met-enk, and
Leu-enk) have been isolated from bovine adrenal medulla (39). The
numbers above each cleavage site represent the internally
quenched peptides that were synthesized for this study.
|
|
Determination of Specificity Constants
(kcat/Km) of PC2 for PE-derived Internally Quenched
Fluorogenic Substrates--
Whereas internally quenched peptide
substrate series represent an effective means to determine enzyme
preference at various subsites (25, 29, 40, 41), intermolecular
quenching limits the substrate concentrations that can be employed in a
given experiment to less than 20 µM, making the use of
these substrates for direct Km determinations
problematic. In addition, several internally quenched peptides have
been found to exhibit substrate inhibition, in which initial velocity
decreases at high substrate concentrations, and Michaelis-Menten
kinetics cannot be applied (41). To avoid these complications, pseudo
first-order reaction kinetics were applied to measure the specificity
constants of internally quenched peptides for PC2, since under
conditions where the substrate concentration is far below the
Km, substrate inhibition is not likely to occur.
Fig. 2 depicts the progression of the
digestion of the short peptide B-based sequence (internally quenched
substrate 1 (IQ 1), see Fig. 1) by PC2. The curve was fitted
using nonlinear regression according to Equation 1 under "Materials
and Methods."

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 2.
Graphical representation of the hydrolysis of
an IQ substrate based on peptide B. Time course of cleavage of
Abz-VPEMEKRYGGMFMQ-EDDnp under pseudo first-order reaction conditions
The curve was fitted with a nonlinear regression equation
(see "Materials and Methods").
|
|
Eleven internally quenched fluorogenic substrates containing amino acid
sequences around proenkephalin cleavage sites were subjected to kinetic
analysis to determine PC2 preference (Table I). The results are given from the
highest to the lowest
kcat/Km. Specificity
constants represent the average of replicate hydrolyses performed on
different occasions. MALDI-TOF and HPLC were performed on cleaved IQ
substrates to positively identify cleavage products. In all cases, the
HPLC and the mass spectroscopy results confirmed that PC2 cleaved at
the paired basic site and not at other positions.
View this table:
[in this window]
[in a new window]
|
Table I
Kinetic properties of PC2 on internally quenched substrates and the
fluorogenic peptide pGlu-Arg-Thr-Lys-Arg-MCA
Reactions were determined under pseudo-first order conditions, as
described in the text. Numbers in the left column represent the
positions assigned in the PE precursor as shown in Fig. 1.
indicates cleavage site.
|
|
A 20-fold difference in specificity constants for the various sites
within PE was observed using the IQ substrate series (Table I). A
2-fold difference in IQ 1 versus IQs 8 and 10 was observed, indicating that when the P' residues are constant, PC2 prefers the P
residues of peptide B to other sites. These values were fairly constant
upon replication; there was an approximately 6% margin of error
between replicate determinations for the
kcat/Km values of IQ 1 and
between 2 and 10% errors for IQs 8, 10, and 5. There was little
difference in specificity constants among IQs 8, 10, and 5, which
contain sequences with considerable variability surrounding the Lys-Arg
cleavage sites; these data indicate a fairly wide specificity for
PC2.
PC2 exhibited a preference for Lys-Arg over Lys-Lys pairs for cleavage,
as evidenced by an at least 10-fold difference between the IQ
substrates bearing a Lys-Arg site (IQs 1, 8, 10, and 5) compared with
those with a Lys-Lys (IQs 6, 11, 9, and 4) cleavage site. The only
Arg-Arg-containing substrate tested (IQ 4) had the lowest
kcat/Km, potentially
indicating lesser preference by PC2. Interestingly, charges seemed to
be well tolerated at the P3 and P5 positions (IQs 1 and 8).
We compared the sequences within proenkephalin with the synthetic
fluorogenic substrate (<Glu-Arg-Thr-Lys-Arg-MCA) commonly used for PC
activity determinations. Surprisingly, this short fluorogenic peptide
was found to represent a comparatively good substrate for PC2 (Table
I). PC2 was able to cleave this substrate with a
kcat/Km of 1.90 × 104 M 1 s 1,
comparable to the specificity constants obtained with the much longer
IQ substrates 8, 10, and 5.
To confirm the above kinetic values, independent experiments were
carried out using a different substrate concentration (200 nM) with the three most preferred substrates and the same
enzyme concentration. Specificity constants derived from these
independent experiments resulted in very similar values (within 2-6%;
data not shown). In another series of experiments, IQ substrates 1, 8, and 5 were used with PC2 from another purification (36 nM). The specificity constants from these experiments were slightly lower
(data not shown), but the order of substrate preference was retained.
The discrepancy in specificity constants was attributable to the lower
specific activity of this particular PC2 preparation.
PC2 Prefers Arg at Positions P4 and P5 in the Peptide B IQ
Substrates--
Since the peptide B-based IQ substrate was apparently
the most preferred, we synthesized a series of IQ substrates with the same sequence but substituting Arg and Ala residues at various positions (Table II). Among the
Arg-containing substrates, the greatest difference in
kcat/Km from the original
peptide B-based IQ substrate (IQ 1) was observed with IQ 12, which
contained an Arg at P5 (Table I); the specificity constant of this
particular substrate was twice that of IQ 1. The substrate containing
Arg at P4 (IQ 13) also exhibited an appreciably increased
kcat/Km compared with other
IQ substrates. A substitution of Ala at P5 (IQ 18) resulted in a
decrease in PC2 preference compared with an Arg substitution at this
position (IQ 12). Nonetheless, when IQ 18 (Table II) was compared with
IQ 1, which contains a P5 Glu (Table I), there was no appreciable
decrease in specificity constants, indicating that an amino acid switch
from Glu to Ala at P5 is not detrimental. Slightly decreased
specificity constants were observed when Arg was substituted for Ala at
positions P6 and P7 (IQs 14 and 15 versus IQs 19 and 20).
However, the P4 position appears to play a particularly crucial role in
determining specificity. A 20-fold decrease in PC2 preference was
observed when Ala was substituted for Arg at P4 (IQ 22 versus IQ 13).
View this table:
[in this window]
[in a new window]
|
Table II
Kinetic properties of PC2 on internally quenched peptides
containing Arg and Ala substitutions
The best substrate from Table I, the peptide B analog, was used as a
base to systematically examine the effect of Ala and Arg substitutions.
Results represent the mean of two independent replicate time course
experiments performed at a substrate concentration of 2 µM. indicates the cleavage site.
|
|
In addition to the Ala scan, we also tested the effect of size
preference using peptide B sequences. A 25-amino acid long peptide
B-related substrate (IQ 16) was compared with smaller sized IQ
substrates (it should be noted that natural peptide B is a 31-amino
acid peptide). No appreciable increase in PC2 preference was observed
when the longer IQ 16 (Table I) was compared with the shorter IQ 1 (Table II). These results support the idea that, contrary to furin and
PC1 (24), PC2 does not exhibit a great preference for longer
versus shorter peptides.
For PC1 studies, we tested several IQ substrates that, based upon our
in vivo results on the cleavage of proenkephalin in PC1-containing cell lines (7, 33), we believed would represent good
candidates for cleavage by this enzyme. IQ substrates 1, 2, 5, 7, 9, and 10 were subjected to specificity analysis with PC1 under the same
pseudo first-order reaction rate conditions. Due to the much lower
catalytic rate exhibited by PC1 (0.25 µmol/h/mg) compared with PC2
(29 µmol/h/mg), higher PC1 enzyme concentrations (115 nM)
and longer times of incubation were used in these experiments. kcat/Km values of PC1 for IQs
5 and 2 were 6.4 × 103 and 1.8 × 103, respectively, but no change in the initial
fluorescence value was observed for the other IQ substrates tested (IQs
1, 7, 9, and 10) over a period of several hours, indicating that they
did not serve as substrates. In fact, the specificity constants of IQs
2 and 5 for cleavage by PC1 were fairly low; these results indicate
relatively low PC1 preference for these substrates compared with PC2,
potentially due to the low affinity of PC1 for substrates containing a
P' bulky hydrophobic residue (26).
Synthetic Fluorogenic Substrates: Basic Residues at Positions P1,
P2, and P4 Are Preferred by PC2--
Fig.
3 depicts Lineweaver-Burk analysis of
various fluorogenic substrates by PC2. Note that extremely long times
of incubation (18 h) were required to observe significant hydrolysis of
substrates lacking other basic residues such as Boc-Val-Pro-Arg-MCA.
These analyses, from which the kinetic values shown in Table
III were derived, can be used to infer
binding interactions between the substrate side groups and the PC2
subsites. The presence of basic residues at positions P1, P2, and P4
resulted in substrates with at least 34-fold higher
kcat/Km values than
substrates lacking any of these basic residues (Table III). Data
obtained using substrates 6-8 revealed that a P4 basic residue was
more important in ensuring a lower Km than a P2
basic, although this effect could also be due to the varying substrate
length. Substrate 2, which differed from all the other substrates
containing three basic residues in possessing a Pro residue at the P3
position, displayed almost 3-fold higher kcat
than the next best substrate. Substrate 5, with the unnatural amino
acid Orn at P4, exhibited a higher Km than substrate
3 with a Lys at the same position.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
Lineweaver-Burk analysis of the cleavage of
MCA fluorogenic peptides. A, Cbz-Arg-Ser-Lys-Arg-MCA
( ), <Glu-Arg-Thr-Lys-Arg-MCA ( ), and Ac-Arg-Pro-Lys-Arg-MCA
( ) by 3.7 ng of PC2 after a 6.5 h of incubation; B,
Ac-Arg-Phe-Ala-Arg-MCA by 260 ng of PC2 after 2 h of incubation
( ); Boc-Gly-Lys-Arg-MCA ( ) by 65 ng of PC2 after 18 h of
incubation; and C, Boc-Val-Pro-Arg-MCA ( ) by 65 ng of PC2
after 18 h of incubation. Purified pro-PC2 was preincubated in
assay buffer for 1 h at 37 °C to activate the proenzyme and
then incubated with various concentrations of substrate in the presence
of 100 nM 21-kDa 7B2; initial hydrolysis rates were then
measured. Individual data points represent the means ± S.E.,
n = 3.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Kinetic properties of the hydrolysis of fluorogenic peptidyl MCA
substrates
Concentrations of the enzyme and incubation times are as shown in
Figure 3. Values represent the mean ± S.E. (N = 3).
|
|
A preference for an Arg residue at the P1 position over Lys may exist
since substrate 10, unlike substrate 9, was not appreciably hydrolyzed.
Except for substrate 1, whose 3-fold higher specificity constant is
attributable to its 3-fold lower Km, the specificity
of PC2 for substrates 3, 4, and 5 (which displayed comparable
kcat values to substrate 1) was influenced more
by Vmax than by Km. There was
a higher degree of tolerance at the P3 position than at all the other
positions examined.
PC2 Does Not Require Prior Action of PC1 in Processing
Proenkephalin (PE) in Vitro--
In order to investigate the
processing of recombinant PE by the recombinant prohormone convertases,
purified PC1 (0.24 µg, final concentration 72 nM) and PC2
(0.24 µg, 55 nM) were incubated with recombinant PE (1.25 µg, 0.91 µM) for either 0, 10, 30, 60, 90, or 120 min;
aliquots of reaction mixtures were then subjected to Western blotting
(Fig. 4). The 1st
lane in each panel shows the band corresponding to PE at
zero time. Thirty minutes later, peptides with apparent molecular
masses of 30, 23, and 16 kDa were observed in both digestion reactions
(Fig. 4, A and B). These experiments showed that
in roughly equal enzyme concentrations, PC2 was much more efficient
than PC1 in cleaving PE. After 60 min of incubation, 26- and 18-kDa
peptides were present as additional PC2 digestion products. At 90 min
of digestion, PE was more than 50% digested in PC2-containing samples.
By using comparable amounts of enzyme, 2 h after the incubation
period PE was completely processed by PC2, unlike PC1-containing
samples that were less than 50% digested at this time. Chromaffin
granule protein was immunoblotted along with these digests (Fig.
4A, 7th lane) in order to compare the natural pattern of
processing with that resulting from the in vitro
experiments. Except for the intermediate with an approximate molecular
mass of 23 kDa, the remaining peptides possessed slightly different
molecular masses. This might be due to the fact that in
vitro, but not in vivo, these peptides would be
expected to contain dibasic residue extensions. It should be noted that
the blotting method will only detect larger intermediate peptides resulting from PE digestion, as smaller peptides such as peptide F
would be expected to wash off of the blot during the procedure. Indeed,
the disappearance of peptide F-immunoreactive fragments over time
represents indirect evidence that further cleavage into smaller
peptides occurred with PC2 but not PC1-digested PE.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 4.
Processing of recombinant proenkephalin by
PC1 and PC2: Western blotting. PE (1.25 µg) was incubated with
either preincubated PC1 (A) and PC2 (B), and
reaction mixtures were subjected to Western blotting with antiserum
against peptide F. Chromaffin granule protein (chrom. gr)
was included in this blot. Molecular mass standards are
indicated.
|
|
PC2-mediated Cleavage of Proenkephalin Results in the Formation of
Small Enkephalins--
High pressure gel permeation chromatography was
used to separate the reaction products of proenkephalin with PC2; RIAs
of Met-enk-Arg-Phe, Met-enk, and Leu-enk were used to identify
enkephalin-containing peptides (Fig. 5).
PC2 was able to produce low molecular weight enkephalins (500-1000
Da) including Met-enk-Arg-Phe, Leu-enk, and Met-enk, unlike
PC1 which could only generate intermediate-sized enkephalins of 3 kDa
and larger (42).2

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
In vitro processing of recombinant
proenkephalin by PC2: size separation and RIA analysis. Following
HPGPC of reaction mixtures, enkephalin radioimmunoassays were performed
on aliquots of fractions. B and C, samples were
digested with trypsin and carboxypeptidase B prior to RIA to reveal
immunoreactivity contained within larger fragments. A,
Met-enk-Arg-Phe; B, Leu-enkephalin; C,
Met-enkephalin. Arrows indicate the elution positions of the
standards used: PE (proenkephalin); peptide B
(B), Met-enk-Arg-Phe, peptide E (E), Leu-enk,
peptide F (F), and Met-enk.
|
|
PC2-Knock-out Mouse Brain Is Greatly Depleted of
Enkephalins--
Fig. 6 shows the
profile of immunoreactive enkephalins in the brains of wild-type or
PC2-knock-out animals. It should be noted that the small enkephalins
resulting from recombinant PE cleavage exhibited slightly different
elution times when compared with the in vivo knock-out
experiments, since the presence of the salts in the reaction mixture
tends to affect the elution
profile.3 The Fig.
6A depicts Met-enk-Arg-Phe-immunoreactive peptides; the
amount of mature Met-enk-Arg-Phe, usually the predominant immunoreactive peptide in brain (43, 44) is severely diminished in the
PC2-knock-out animal, with a concomitant increase in the amount of the
immediate precursor, peptide B. Digestion of precursors with trypsin
and carboxypeptidase B was required to liberate the cryptic
immunoreactivity in intermediates prior to assay for Leu-enk (Fig.
6B) and Met-enk (Fig. 6C). Again, the amount of
mature enkephalins was severely depleted in the knock-out animals, and
the Met-enk assay showed increased levels of Met-enk-containing
precursors.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of enkephalins in PC2-knock-out and
wild-type mouse brain. Frozen brains from knock-out
(KO) and wild-type (WT) control mice were
homogenized and centrifuged, and an aliquot of the supernatant was
subjected to HPGPC. Enkephalin RIAs were then performed on duplicate
aliquots of fractions. B and C, aliquots were
digested with trypsin and carboxypeptidase B prior to RIA to reveal
immunoreactivity contained within larger fragments. Closed
circles, wild-type brain; open circles, PC2-knock-out
brain. A, Met-enk-Arg-Phe; B, Leu-enkephalin;
C, Met-enkephalin. Arrows indicate the elution
positions of the standards used: PE (proenkephalin), peptide
B (B), Met-enk-Arg-Phe, peptide E (E), Leu-enk,
peptide F (F), and Met-enk.
|
|
 |
DISCUSSION |
There is a large body of evidence implicating PC1 and PC2 in
prohormone and proneuropeptide processing (reviewed in Refs.1 and 2).
However, little information is available in relation to the specificity
of each of these enzymes as well as to the kinetic properties of PCs on
natural substrates. In the present study we have attempted to gain
information on the preferences of PC2 at various substrate subsites as
well as to examine the contribution of each prohormone convertase to
the cleavage of proenkephalin and proenkephalin-related peptides.
Eleven internally quenched peptides (from P7 or P6 to P'5) with PE
cleavage site sequences were subjected to kinetic analysis to determine
specificity constants of these IQ substrates. PC2 showed a great
preference for the peptide B dodecapeptide sequence (IQ 1, Table I);
however, unlike PC1, most other sites were cleaved with reasonable
efficiency, supporting the wider specificity of PC2 as opposed to PC1.
The preference of PC2 for the peptide B cleavage to Met-enk-Arg-Phe is
in agreement with our in vivo experiments in PE-transfected
AtT-20 cells (6). In these studies, cells coexpressing PC2 produced
greater quantities of mature PE-derived peptides such as
Met-enk-Arg-Phe and Met-enk-Arg-Gly-Leu compared with control cells
expressing only PC1. Similarly, Rin cells in which PC2 synthesis was
blocked through antisense expression exhibited diminished production of
active enkephalins (6). Taken together with our previous in
vivo results (6), the in vitro specificity data
presented here provide further support for the role of PC2 in the
production of small opioid-active enkephalins.
In support of the preference of PC2 for peptide B, in vitro
experiments have demonstrated efficient cleavage of synthetic peptide B
by PC2 as assessed by an HPLC peptide cleavage assay (Km = 89 µM; kcat = 0.47 s 1).2 These results showing relatively high
Km values of PC2 with putative natural peptide
substrates are in agreement with recent work of others using our
recombinant PC2, such as the conversion of CCK33 to CC8 with a
Km of 105 µM (20) and the conversion of pro-NPY with a Km of 69 µM (45). It
is interesting to note that, contrary to PC1 (24), PC2 exhibits neither
a higher turnover nor a better affinity for larger peptide substrates, potentially indicating that the minimal substrate-binding site in PC2
may not be as extensive as that in PC1.
We then performed specificity studies with internally quenched peptides
based upon peptide B but containing substitutions of either an Arg or
an Ala at different positions. Although most of these substituted
peptides showed respectable
kcat/Km values of >1 × 104 M 1 s 1, a
dramatic improvement in PC2 preference was observed when Arg was
substituted at either P5 or P4, an unexpected result since none of the
natural proenkephalin peptides possess either P4 or P5 basic residues.
In similar kinetic studies with pro-parathyroid hormone-related
internally quenched substrates cleaved by furin and PC1 (46), a P4
Arg-containing sequence (GSRKKR-SVSE) was preferred by these enzymes by
3-5-fold. Recent data obtained from peptide combinatorial library
screening in our laboratory support a preference for Arg at P4 for both
PC1 and PC2.4
IQ substrate series are invaluable in examining PC2 specificity and
sequence preferences, but when used under pseudo first-order reaction
conditions they cannot yield the individual contributions of the
Km and the Vmax to the
specificity constant. We examined these parameters using a series of
fluorogenic substrates which when cleaved yield the highly fluorescent
product amino methyl coumarin. The specificity constants for the
hydrolysis of various fluorogenic substrates by PC2 (Table III)
distinguish three classes of substrates as follows: those with three
basic residues at the P1, P2, and P4 subsites; those with two basic residues, an Arg at P1 and another at one of the other preferred basic
residue-binding sites (P2 or P4); and the last group, only slightly
hydrolyzed, which had only a single basic residue occupying the P1
subsite. These results are in complete accord with our IQ substrate
data in which the presence of a dibasic pair (i.e. Lys-Arg)
at P1 and P2 and an Arg at P4 resulted in the highest specificity
constant for PC2 of all of the IQ substrates studied. This pattern is
also in agreement with other kinetic studies on the mammalian
convertases that demonstrated that for maximal hydrolysis rates by PC1
(17, 31) and by furin (31, 46, 47), these three subsites must be
occupied by basic residues. Non-kinetic surveys of various fluorogenic
substrates using PC1 and furin revealed a similar trend (9, 11, 17,
48). Substrate phage display experiments using furin demonstrated a
requirement for a P1 basic residue in conjunction with a P2 and/or a P4
basic residue (49). This requirement for a P4 basic residue appears to
be restricted to the mammalian enzymes, as studies with the yeast
proteinase kex2 showed an effect neither on Km nor
on kcat by a P4 basic residue (50). It should be
noted that most PC1 and PC2 substrates do not contain a P4 basic
residue; therefore, this preference may exist for the benefit of other reactions, such as autocatalysis of proenzyme cleavage, which is
thought in the case of pro-PC2 to occur at two tetrabasic sequences within the proregion (51,
52).5
The specificity pattern displayed by the mammalian proprotein
convertases has been attributed to the presence of negatively charged
binding pockets that interact with positively charged substrate side
groups (53, 54); however, the mutational studies that would confirm
this in the case of the PCs have not yet been performed. For PC2, the
importance of charge versus length of the side chain in
enzyme binding was demonstrated by the fluorogenic substrate containing
a substitution of Orn at the P4 position, which exhibited a 3-fold
increased Km compared to similar substrates with a
P4 Arg or Lys. This weaker binding may be attributable to the shorter
side group of Orn and could indicate that a negative charge located
deep inside the S4 subsite of the enzyme is important for effective
electrostatic interaction. Interestingly, when Orn versus
Arg and Lys substitution studies were performed using human PC1 and
furin, a P4 Orn also had a marked deleterious effect on PC1 (18-fold
drop in kcat/Km compared with
Arg, attributable mainly to an effect on Km) and an
even greater effect on furin (280-fold reduction in
kcat/Km, due mainly to kcat) (31). Since our results with PC2 resemble
PC1 more than furin, the P4 subsite of PC2 may be more similar to that
of PC1 than to that of furin.
The P3 position within the substrate appears to represent a position
where more tolerance is generally allowed, for kex2 (41, 50), PC1 (31)
and furin (49), although acidic residues in this position are
discriminated against by furin (31). Our results with PC2 support the
idea that substitution at the P3 position resulted in relatively mild
effects on the kinetics of substrate hydrolysis. Apart from MCA
substrate 2, which contained a P3 Pro and displayed a 3-fold higher
kcat than the other substrates, various
substitutions at this position did not reveal any significant side
group preferences, and this conclusion was further supported by the IQ
substrate data. The P3 Pro preference for PC2 appears to be unusual for
this family of enzymes; Pro was not selected in a furin phage display
study at this position (49), and in a quenched fluorescent peptide
study a P3 Pro decreased rather than increased the specificity
constants of furin and PC1 (31).
Our IQ substrate data indicate that substitutions of Arg at P6 and P7
were well accepted by PC2 compared with Ala at this position,
indicating that positively charged residues at these positions neither
improved nor were detrimental for PC2 recognition. These positions may
therefore not be as important to determining PC2 specificity as the P1
to P4 residues; however, other substitutions will have to be tested to
substantiate this conclusion. Similar results were observed in
experiments with other internally quenched peptides in which PC1
tolerated considerable variety at the P6 position (46).
In order to examine the cleavage of a known physiological precursor
with PC2, we analyzed the reaction of recombinant PE with PC1 and PC2
using Western blotting and RIA. These studies showed that PC2 was quite
capable of cleaving PE without prior action of PC1, although this in
all likelihood does not represent the physiological reaction in tissues
expressing both enzymes, since PC1 may be available for catalytic
action earlier in the secretory pathway than PC2 (55). Assays of
size-separated immunoreactive enkephalins showed that whereas PC1 was
unable to cleave peptide B in vitro to form
Met-enk-Arg-Phe,2 PC2 readily performed this cleavage, and
a major peak corresponding to this heptapeptide was observed. Overall,
in agreement with the natural profile of enkephalin-containing peptides
in tissues (34, 39, 44), distinct groups of peptides with
characteristic sizes were generated by each enzyme; PC1 generated
larger intermediates, and PC2 generated small peptides. However, some
discrepancies were observed, such as the absolute inability of PC1 to
perform the cleavage of either the IQ substrate containing the peptide B sequence (Table I) or the cleavage of synthetic peptide B to Met-enk-Arg-Phe in vitro2 compared with the
known presence of this heptapeptide in AtT-20 cells, which are thought
to express only PC1 (55). The reasons for these discrepancies are not
clear at present but may have to do with the presence of very small
quantities of PC2 in AtT-20 cells (56) or cellular contributions to
substrate selectivity.
We also analyzed the contribution of PC2 to total PE processing
in vivo by performing enkephalin RIAs on wild-type and
PC2-knock-out mouse brain extracts. Taken together with previous
in vivo and in vitro results (6, 33) and the
findings presented here, these data support the notion that the
predominant enzyme responsible for the production of the opioid-active
mature penta- to octapeptide enkephalins in normal brain is PC2. The
fact that no obvious diminution of brain function occurred in these
animals in the face of such severe depletion of opioids indicates the
potential presence of surplus functional neuropeptide in normal animals
(27), potentially similar to the extreme depletion of dopamine required
for the observation of Parkinson's-like symptoms. Alternatively,
developmental compensation could have occurred in the PC2 knock-out
animals to employ alternative neurotransmitters in peptide-containing pathways.
There is disagreement as to the primary enzymes involved in the
physiological cleavage of proenkephalin. Whereas a recent report has
implicated an enzyme known as prohormone thiol protease as the
principal enzyme involved in PE cleavage (4), the involvement of PC1
and PC2 in peptide hormone processing has been widely accepted (1, 2).
The present investigation provides strong support for the idea that
PC2, which our data show possesses the necessary specificity to play a
primary role in the physiological processing of PE-derived
intermediates, actually does so in vivo.
 |
ACKNOWLEDGEMENTS |
We are grateful to Francois Jean for the
synthesis of the peptidyl-MCA substrates. We thank Joelle Finley for
assistance with the bioreactors, Elizabeth Guerra for help with the
radioimmunoassays, and Nathan Rockwell for advice in setting up the
IQ substrate experiments.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant DA05084 (to I. L.) and by MRC Grant PG-11474 from the Medical Research Council of Canada (to C. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Supported by Fundação de Amparo à Pesquisa
do Estado de São Paulo (FAPESP) and Conselho Nacional de
Desenvolvimento Científico e Tecnológico (CNPq).

Supported by K02 Award DA00204 from the National Institutes of
Health. To whom correspondence should be addressed: Louisiana State
University Medical Center, School of Medicine, Dept. of Biochemistry,
1901 Perdido St., New Orleans, LA 70112. Tel.: 504-568-4799; Fax:
504-568-3370; E-mail: ilindb{at}lsumc.edu.
The abbreviations used are:
PC1, prohormone
convertase 1; PC2, prohormone convertase 2; IQ, internally quenched; Abz, ortho-aminobenzoic acidMCA, methylcoumarin amideEDDnp, N-(2,4-dinitrophenyl)ethylenediamine)HPGPC, high
pressure gel permeation chromatographyLeu-enk, Leu-enkephalinMCA, methylcoumarin amide<Glu, pyroglutamic acidBoc, t-butoxycarbonylMet-enk, met-enkephalinBis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diolPE, proenkephalinRIA, radioimmunoassayMALDI-TOF, mass spectroscopy
laser desorption ionization-time of flightHPLC, high pressure liquid
chromatography.
2
K. Johanning and I. Lindberg, unpublished
data.
3
K. Johanning, unpublished data.
4
E. Apletalina, J. Appel, N. S. Lamango, R. A. Houghten, and I. Lindberg, submitted for publication.
5
N. S. Lamango, E. Apletalina, J. Liu, and
I. Lindberg, submitted for publication.
 |
REFERENCES |
-
Mains, R. E.,
Dickerson, I. M.,
May, V.,
Stoffers, D. A.,
Perkins, S. N.,
Ouafik, L.,
Husten, E. J.,
and Eipper, B.
(1990)
Front. Neuroendocrinol.
11,
52-89
-
Rouille, Y.,
Duguay, S. J.,
Lund, K.,
Furuta, M.,
Gong, Q.,
Lipkind, G.,
Oliva, A. A., Jr.,
Chan, S. J.,
and Steiner, D. F.
(1995)
Front. Neuroendocrinol.
16,
322-361[CrossRef][Medline]
[Order article via Infotrieve]
-
Brakch, N.,
Rholam, M.,
Boussetta, H.,
and Cohen, P.
(1993)
Biochemistry
32,
4925-4930[CrossRef][Medline]
[Order article via Infotrieve]
-
Hook, V. Y. H.,
Schiller, M. R.,
and Azaryan, A. V.
(1996)
Arch. Biochem. Biophys.
328,
107-114[CrossRef][Medline]
[Order article via Infotrieve]
-
Breslin, M. B.,
Lindberg, I.,
Benjannet, S.,
Mathis, J. P.,
Lazure, C.,
and Seidah, N. G.
(1993)
J. Biol. Chem.
268,
27084-27093[Abstract/Free Full Text]
-
Johanning, K.,
Mathis, J. P.,
and Lindberg, I.
(1996)
J. Neurochem.
66,
898-907[Medline]
[Order article via Infotrieve]
-
Mathis, J.,
and Lindberg, I.
(1992)
Endocrinology
131,
2287-2296[Abstract/Free Full Text]
-
Seidah, N. G.,
Gaspar, L.,
Mion, P.,
Marcinkiewicz, M.,
Mbikay, M.,
and Chretien, M.
(1990)
DNA Cell Biol.
9,
415-424[Medline]
[Order article via Infotrieve]
-
Zhou, Y.,
and Lindberg, I.
(1993)
J. Biol. Chem.
268,
5615-5623[Abstract/Free Full Text]
-
Jean, F.,
Basak, A.,
Rondeau, N.,
Benjannet, S.,
Hendy, G. N.,
Seidah, N. G.,
Chretien, M.,
and Lazure, C.
(1993)
Biochem. J.
292,
891-900
-
Rufaut, N. W.,
Brennan, S. O.,
Hakes, D. J.,
Dixon, J. E.,
and Birch, N. P.
(1993)
J. Biol. Chem.
268,
20291-20298[Abstract/Free Full Text]
-
Lamango, N. S.,
Zhu, X.,
and Lindberg, I.
(1996)
Arch. Biochem. Biophys.
330,
238-250[CrossRef][Medline]
[Order article via Infotrieve]
-
Friedman, T. C.,
Loh, Y. P.,
and Birch, N. P.
(1994)
Endocrinology
135,
854-862[Abstract]
-
Friedman, T. C.,
Gordon, V. M.,
Leppla, S. H.,
Klimpel, K. R.,
Birch, N. P.,
and Loh, Y. P.
(1995)
Arch. Biochem. Biophys.
316,
5-13[CrossRef][Medline]
[Order article via Infotrieve]
-
Nillni, E. A.,
Friedman, T. C.,
Todd, R. B.,
Birch, N. P.,
Loh, Y. P.,
and Jackson, I. M.
(1995)
J. Neurochem.
65,
2462-2472[Medline]
[Order article via Infotrieve]
-
Dupuy, A.,
Lindberg, I.,
Zhou, Y.,
Akil, H.,
Lazure, C.,
Chretien, M.,
Seidah, N. G.,
and Day, R.
(1994)
FEBS Lett.
337,
60-65[CrossRef][Medline]
[Order article via Infotrieve]
-
Ledgerwood, E. C.,
Brennan, S. O.,
Birch, N. P.,
and George, P. M.
(1996)
Biochem. Mol. Biol. Int.
39,
1167-1176[Medline]
[Order article via Infotrieve]
-
Rothenberg, M. E.,
Eilertson, C. D.,
Klein, K.,
Zhou, Y.,
Lindberg, I.,
McDonald, J. K.,
Mackin, R. B.,
and Noe, R. B.
(1995)
J. Biol. Chem.
270,
10136-10146[Abstract/Free Full Text]
-
Rouille, Y.,
Bianchi, M.,
Irminger, J. C.,
and Halban, P. A.
(1997)
FEBS Lett.
413,
119-123[CrossRef][Medline]
[Order article via Infotrieve]
-
Wang, W.,
and Beinfeld, M. C.
(1997)
Biochem. Biophys. Res. Commun.
231,
149-152[CrossRef][Medline]
[Order article via Infotrieve]
-
Day, R.,
Lazure, C.,
Basak, A.,
Boudreault, A.,
Limperis, P.,
Dong, W.,
and Lindberg, I.
(1998)
J. Biol. Chem.
273,
829-836[Abstract/Free Full Text]
-
Brakch, N.,
Rist, B.,
Beck-Sickinger, A. G.,
Goenaga, J.,
Wittek, R.,
Burger, E.,
Brunner, H. R.,
and Grouzmann, E.
(1997)
Biochemistry
36,
16309-16320[CrossRef][Medline]
[Order article via Infotrieve]
-
Furuta, M.,
Carroll, R.,
Martin, S.,
Swift, H. H.,
Ravazzola, M.,
Orci, L.,
and Steiner, D. F.
(1998)
J. Biol. Chem.
273,
1-7[Free Full Text]
-
Bailyes, E. M.,
Shennan, K. I. J.,
Usac, E. F.,
Arden, S. D.,
Guest, P. C.,
Docherty, K.,
and Hutton, J. C.
(1995)
Biochem. J.
309,
587-594
-
Jean, F.,
Basak, A.,
Dimaio, J.,
Seidah, N. G.,
and Lazure, C.
(1995)
Biochem. J.
307,
689-695
-
Basak, A.,
Schmidt, C.,
Ismail, A. F.,
Seidah, N. G.,
Chretien, M.,
and Lazure, C.
(1995)
Int. J. Pept. Protein Res.
46,
228-237[Medline]
[Order article via Infotrieve]
-
Furuta, M.,
Yano, H.,
Zhou, A.,
Rouille, Y.,
Holst, J. J.,
Carroll, R.,
Ravazzola, M.,
Orci, L.,
Furuta, H.,
and Steiner, D. F.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6646-6651[Abstract/Free Full Text]
-
Hirata, Y.,
Cezari, M. H. S.,
Nakaie, C. R.,
Boschcov, P.,
Ito, A. S.,
Juliano, M. A.,
and Juliano, L.
(1994)
Lett. Peptide Sci.
1,
299-308
-
Del Nery, E.,
Juliano, M. A.,
Meldal, M.,
Svendsen, I.,
Scharfstein, J.,
Walmsley, A.,
and Juliano, L.
(1997)
Biochem. J.
323,
427-433
-
Lindberg, I.,
Shaw, E.,
Finley, J.,
Leone, D.,
and Deininger, P.
(1991)
Endocrinology
128,
1849-1856[Abstract/Free Full Text]
-
Jean, F.,
Boudreault, A.,
Basak, A.,
Seidah, N. G.,
and Lazure, C.
(1995)
J. Biol. Chem.
270,
19225-19231[Abstract/Free Full Text]
-
Christie, D. L.,
Birch, N. P.,
Aitken, J. F.,
Harding, D. R.,
and Hancock, W. S.
(1984)
Biochem. Biophys. Res. Commun.
120,
650-656[CrossRef][Medline]
[Order article via Infotrieve]
-
Johanning, K.,
Mathis, J. P.,
and Lindberg, I.
(1996)
J. Biol. Chem.
271,
27871-27878[Abstract/Free Full Text]
-
Lindberg, I.,
and Yang, H. Y.
(1984)
Brain Res.
299,
73-78[CrossRef][Medline]
[Order article via Infotrieve]
-
Lindberg, I.,
and Thomas, G.
(1990)
Endocrinology
126,
480-487[Abstract/Free Full Text]
-
Mocchetti, I.,
Giorgi, O.,
Schwartz, J. P.,
and Costa, E.
(1984)
Eur. J. Pharmacol.
106,
427-430[CrossRef][Medline]
[Order article via Infotrieve]
-
Giraud, P.,
Eiden, L. E.,
Audigier, Y.,
Gillioz,
Conte-Devols, B.,
Bourdouresque, F.,
Eskay, R.,
and Oliver, C.
(1981)
Neuropeptides
1,
237-252[CrossRef]
-
Lindberg, I.,
and Shaw, E.
(1992)
J. Neurochem.
58,
448-453[CrossRef][Medline]
[Order article via Infotrieve]
-
Udenfriend, S.,
and Kilpatrick, D. L.
(1983)
Arch. Biochem. Biophys.
221,
309-323[CrossRef][Medline]
[Order article via Infotrieve]
-
Angliker, H.,
Neumann, U.,
Molloy, S. S.,
and Thomas, G.
(1995)
Anal. Biochem.
224,
409-412[CrossRef][Medline]
[Order article via Infotrieve]
-
Rockwell, N. C.,
Wang, G. T.,
Krafft, G. A.,
and Fuller, R. S.
(1997)
Biochemistry
36,
1912-1917[CrossRef][Medline]
[Order article via Infotrieve]
-
Zhou, Y.,
and Lindberg, I.
(1994)
J. Biol. Chem.
269,
18408-18413[Abstract/Free Full Text]
-
Lindberg, I.,
and White, L.
(1986)
Biochem. Biophys. Res. Commun.
139,
1024-1032[CrossRef][Medline]
[Order article via Infotrieve]
-
Birch, N. P.,
and Christie, D. L.
(1986)
J. Biol. Chem.
261,
12213-12221[Abstract/Free Full Text]
-
Brakch, N.,
Rist, B.,
Beck-Sickinger, A. G.,
Goenaga, J.,
Wittek, R.,
Burger, E.,
Brunner, H. R.,
and Grouzmann, E.
(1997)
Biochemistry
36,
16309-16320
-
Lazure, C.,
Gauthier, D.,
Jean, F.,
Boudreault, A.,
Seidah, N. G.,
Bennett, H. P. J.,
and Hendy, G.
(1998)
J. Biol. Chem.
273,
8572-8580[Abstract/Free Full Text]
-
Hatsuzawa, K.,
Nagahama, M.,
Takahashi, K.,
Takada, K.,
Murakami, K.,
and Nakayama, K.
(1992)
J. Biol. Chem.
267,
16094-16099[Abstract/Free Full Text]
-
Leduc, R.,
Molloy, S. S.,
Thorne, B. A.,
and Thomas, G.
(1992)
J. Biol. Chem.
267,
14304-14308[Abstract/Free Full Text]
-
Matthews, D. J.,
Goodman, L. J.,
Gorman, C. M.,
and Wells, J. A.
(1994)
Protein Sci.
3,
1197-1205[Medline]
[Order article via Infotrieve]
-
Brenner, C.,
and Fuller, R. S.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
922-926[Abstract/Free Full Text]
-
Matthews, G.,
Shennan, K. I. J.,
Seal, A. J.,
Taylor, N. A.,
Colman, A.,
and Docherty, K.
(1994)
J. Biol. Chem.
269,
588-592[Abstract/Free Full Text]
-
Christie, D. L.,
Batchelor, D. C.,
and Palmer, D. J.
(1991)
J. Biol. Chem.
266,
15679-15683[Abstract/Free Full Text]
-
Roebroek, A. J. M.,
Creemers, J. W. M.,
Ayoubi, T. A. Y.,
and Van de Ven, W. J. M.
(1994)
Biochimie (Paris)
76,
210-216[Medline]
[Order article via Infotrieve]
-
Siezen, R. J.,
Creemers, J. W. M.,
and Van de Ven, W. J. M.
(1994)
Eur. J. Biochem.
222,
255-266[Medline]
[Order article via Infotrieve]
-
Zhou, A.,
and Mains, R. E.
(1994)
J. Biol. Chem.
269,
17440-17447[Abstract/Free Full Text]
-
Day, R.,
Schafer, M. K. H.,
Watson, S. J.,
Chretien, M.,
and Seidah, N. G.
(1992)
Mol. Endocrinol.
6,
485-497[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S.-R. Hwang, C. Garza, C. Mosier, T. Toneff, E. Wunderlich, P. Goldsmith, and V. Hook
Cathepsin L Expression Is Directed to Secretory Vesicles for Enkephalin Neuropeptide Biosynthesis and Secretion
J. Biol. Chem.,
March 30, 2007;
282(13):
9556 - 9563.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Scamuffa, F. Calvo, M. Chretien, N. G. Seidah, and A.-M. Khatib
Proprotein convertases: lessons from knockouts
FASEB J,
October 1, 2006;
20(12):
1954 - 1963.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pasquato, P. Pullikotil, M.-C. Asselin, M. Vacatello, L. Paolillo, F. Ghezzo, F. Basso, C. Di Bello, M. Dettin, and N. G. Seidah
The Proprotein Convertase SKI-1/S1P: IN VITRO ANALYSIS OF LASSA VIRUS GLYCOPROTEIN-DERIVED SUBSTRATES AND EX VIVO VALIDATION OF IRREVERSIBLE PEPTIDE INHIBITORS
J. Biol. Chem.,
August 18, 2006;
281(33):
23471 - 23481.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Kacprzak, M. E. Than, L. Juliano, M. A. Juliano, W. Bode, and I. Lindberg
Mutations of the PC2 Substrate Binding Pocket Alter Enzyme Specificity
J. Biol. Chem.,
September 9, 2005;
280(36):
31850 - 31858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. X. Cawley, J. Zhou, J. M. Hill, D. Abebe, S. Romboz, T. Yanik, R. M. Rodriguiz, W. C. Wetsel, and Y. P. Loh
The Carboxypeptidase E Knockout Mouse Exhibits Endocrinological and Behavioral Deficits
Endocrinology,
December 1, 2004;
145(12):
5807 - 5819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dey, C. Norrbom, X. Zhu, J. Stein, C. Zhang, K. Ueda, and D. F. Steiner
Furin and Prohormone Convertase 1/3 Are Major Convertases in the Processing of Mouse Pro-Growth Hormone-Releasing Hormone
Endocrinology,
April 1, 2004;
145(4):
1961 - 1971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Laurent, L. Jaubert-Miazza, R. Desjardins, R. Day, and I. Lindberg
Biosynthesis of Proopiomelanocortin-Derived Peptides in Prohormone Convertase 2 and 7B2 Null Mice
Endocrinology,
February 1, 2004;
145(2):
519 - 528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Vincent, Y. Guz, M. Rozenberg, G. Webb, M. Furuta, D. Steiner, and G. Teitelman
Abrogation of Protein Convertase 2 Activity Results in Delayed Islet Cell Differentiation and Maturation, Increased {alpha}-Cell Proliferation, and Islet Neogenesis
Endocrinology,
September 1, 2003;
144(9):
4061 - 4069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yasothornsrikul, D. Greenbaum, K. F. Medzihradszky, T. Toneff, R. Bundey, R. Miller, B. Schilling, I. Petermann, J. Dehnert, A. Logvinova, et al.
Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter
PNAS,
August 5, 2003;
100(16):
9590 - 9595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. TAYLOR, W. J. M. VAN DE VEN, and J. W. M. CREEMERS
Curbing activation: proprotein convertases in homeostasis and pathology
FASEB J,
July 1, 2003;
17(10):
1215 - 1227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dey, X. Xhu, R. Carroll, C. W. Turck, J. Stein, and D. F. Steiner
Biological Processing of the Cocaine and Amphetamine-regulated Transcript Precursors by Prohormone Convertases, PC2 and PC1/3
J. Biol. Chem.,
April 18, 2003;
278(17):
15007 - 15014.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Cornwall, A. Cameron, I. Lindberg, D. M. Hardy, N. Cormier, and N. Hsia
The Cystatin-Related Epididymal Spermatogenic Protein Inhibits the Serine Protease Prohormone Convertase 2
Endocrinology,
March 1, 2003;
144(3):
901 - 908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhu, A. Zhou, A. Dey, C. Norrbom, R. Carroll, C. Zhang, V. Laurent, I. Lindberg, R. Ugleholdt, J. J. Holst, et al.
Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects
PNAS,
August 6, 2002;
99(16):
10293 - 10298.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Rockwell and R. S. Fuller
Specific Modulation of Kex2/Furin Family Proteases by Potassium
J. Biol. Chem.,
May 10, 2002;
277(20):
17531 - 17537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Laurent, A. Kimble, B. Peng, P. Zhu, J. E. Pintar, D. F. Steiner, and I. Lindberg
Mortality in 7B2 null mice can be rescued by adrenalectomy: Involvement of dopamine in ACTH hypersecretion
PNAS,
February 14, 2002;
(2002)
261715099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q.-L. Li, E. Jansen, G. A. Brent, and T. C. Friedman
Regulation of prohormone convertase 1 (PC1) by thyroid hormone
Am J Physiol Endocrinol Metab,
January 1, 2001;
280(1):
E160 - E170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. V. Apletalina, L. Muller, and I. Lindberg
Mutations in the Catalytic Domain of Prohormone Convertase 2 Result in Decreased Binding to 7B2 and Loss of Inhibition with 7B2 C-terminal Peptide
J. Biol. Chem.,
May 5, 2000;
275(19):
14667 - 14677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.S.H. Yeo, I.S. Farooqi, B.G. Challis, R.S. Jackson, and S. O'Rahilly
The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models
QJM,
January 1, 2000;
93(1):
7 - 14.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zhou, G. Webb, X. Zhu, and D. F. Steiner
Proteolytic Processing in the Secretory Pathway
J. Biol. Chem.,
July 23, 1999;
274(30):
20745 - 20748.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Apletalina, J. Appel, N. S. Lamango, R. A. Houghten, and I. Lindberg
Identification of Inhibitors of Prohormone Convertases 1 and 2 Using a Peptide Combinatorial Library
J. Biol. Chem.,
October 9, 1998;
273(41):
26589 - 26595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Muller, A. Cameron, Y. Fortenberry, E. V. Apletalina, and I. Lindberg
Processing and Sorting of the Prohormone Convertase 2 Propeptide
J. Biol. Chem.,
December 8, 2000;
275(50):
39213 - 39222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Goumon, K. Lugardon, P. Gadroy, J.-M. Strub, I. D. Welters, G. B. Stefano, D. Aunis, and M.-H. Metz-Boutigue
Processing of Proenkephalin-A in Bovine Chromaffin Cells. IDENTIFICATION OF NATURAL DERIVED FRAGMENTS BY N-TERMINAL SEQUENCING AND MATRIX-ASSISTED LASER DESORPTION IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY
J. Biol. Chem.,
December 1, 2000;
275(49):
38355 - 38362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mzhavia, Y. Berman, F.-Y. Che, L. D. Fricker, and L. A. Devi
ProSAAS Processing in Mouse Brain and Pituitary
J. Biol. Chem.,
February 23, 2001;
276(9):
6207 - 6213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Furuta, A. Zhou, G. Webb, R. Carroll, M. Ravazzola, L. Orci, and D. F. Steiner
Severe Defect in Proglucagon Processing in Islet A-cells of Prohormone Convertase 2 Null Mice
J. Biol. Chem.,
July 13, 2001;
276(29):
27197 - 27202.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Laurent, A. Kimble, B. Peng, P. Zhu, J. E. Pintar, D. F. Steiner, and I. Lindberg
Mortality in 7B2 null mice can be rescued by adrenalectomy: Involvement of dopamine in ACTH hypersecretion
PNAS,
March 5, 2002;
99(5):
3087 - 3092.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|